WVE (WAVE Life Sciences) Moat Score: 4/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WVE WAVE Life Sciences Ltd WVE
59 GF Score
Price $6.01
GF Value $4.36
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is WAVE Life Sciences Moat Score?

WAVE Life Sciences WVE -2.04% 59 Moat Score is 4 as of Jul. 15, 2026. GuruFocus rates WVE with a GF Score™ of 59/100 and a GF Value™ of $4.36 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, WAVE Life Sciences ranks better than 88.75% on this metric.

WAVE Life Sciences has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

WAVE Life Sciences has Narrow Moat: WAVE Life Sciences has discernible advantages through its proprietary technology and ongoing R&D efforts. However, its market share is modest, and it faces significant competition, limiting its moat to a narrow category.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes WAVE Life Sciences might have Narrow Moat - Discernible but modest moat.

WAVE Life Sciences  (NAS:WVE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

WAVE Life Sciences Moat Score Related Terms

WVE vs CGEM, LXRX, XNCR: Moat Score Comparison

For the Biotechnology subindustry, WAVE Life Sciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WAVE Life Sciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Moat Score distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's Moat Score falls into.


WVE
59GF Score
WAVE Life Sciences Ltd WVE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
WAVE Life Sciences (WVE) has a Moat Score of 4 as of Jul. 15, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, WAVE Life Sciences ranks #157 out of 1396 companies in the Biotechnology industry, placing it in the top 11.2%.
Is WAVE Life Sciences' Moat Score too high?
WAVE Life Sciences' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. WAVE Life Sciences' value of 4 is 100% above this industry median. Based on the distribution chart, WAVE Life Sciences ranks #157 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' Moat Score compare to CGEM and LXRX?
According to the Biotechnology industry distribution chart, WAVE Life Sciences ranks #157 out of 1396 companies for Moat Score. This places WAVE Life Sciences in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. WAVE Life Sciences' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WAVE Life Sciences's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WAVE Life Sciences's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (WVE) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.36, compared to a current price of $6.01 — trading 37.8% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For WAVE Life Sciences (WVE), the current Moat Score is 4 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WAVE Life Sciences (WVE) Overvalued in 2026?

Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued. The current stock price of $6.01 is trading 37.8% above its estimated GF Value™ of $4.36. GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.

Key valuation signals for WVE:

  • Moat Score: 4
  • GF Value™: $4.36 vs. price of $6.01 (37.8% above fair value)
  • GF Score™: 59/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1396)

No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WAVE Life Sciences Business Description

Other Exchanges 1U5:Germany
Address 7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score

Get the complete analysis for WVE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.01
Price
$4.36
GF Value